Fuzhou Luyan Pharmacy Secures Exclusive Greater China Rights to French Synergia Brand in Strategic Partnership with Curae LAB

Fuzhou Luyan Pharmacy Co., Ltd. (“Luyan Pharma“) signed an exclusive strategic cooperation agreement with Curae LAB, a subsidiary of the French GTH Group, for the Synergia brand in Greater China. The deal grants Luyan Pharma the exclusive general agency rights to Synergia – a leading professional nutritional health brand under Curae LAB – marking the French group’s distribution push into the Greater China nutritional medicine market.

Deal Snapshot

Partner Profile – GTH Group & Curae LAB

• GTH Group: Founded in 1986, a French independent family‑owned enterprise long engaged in the pharmaceutical and healthcare sector, with a global business footprint.
• Curae LAB: GTH Group subsidiary focused on the R&D, manufacturing, and commercialization of nutritional supplements and medical devices; described as a health product company with profound professional expertise on a global scale.
• Core Mission: Meeting public health needs and enhancing long‑term well‑being.
• Synergia Brand: Curae LAB’s core nutritional health brand, with a long‑term focus on product innovation and application in nutritional medicine.
• Key Therapeutic Areas: Stress management, sleep health, and digestive health – three of the highest‑growth consumer health categories globally.

Strategic Rationale

• Exclusive Market Entry: The agreement gives GTH Group/Curae LAB a dedicated local partner with exclusive Greater China rights, a structure that concentrates channel investment and brand stewardship in a single agency – critical for premium, professionally positioned nutritional brands entering China.
• Pharmacy Channel Fit: As a pharmacy company, Luyan Pharma can route Synergia products through retail pharmacy and professional recommendation channels, aligning with the brand’s positioning in professional nutritional medicine rather than mass‑market supplements.
• Category Alignment: Stress, sleep, and digestive health map directly onto China’s fastest‑expanding consumer health needs, driven by urban lifestyle pressures, aging demographics, and rising self‑care spending.
• Heritage Premium: GTH Group’s four‑decade history and family‑owned independence support a “French professional healthcare” brand narrative – a proven positioning lever for imported health products among Chinese consumers.

Market Impact & Outlook

• China Nutritional Health Landscape: The consumer nutrition market in Greater China continues to expand, with imported, clinically positioned brands competing on trust, formulation quality, and professional endorsement; exclusive agency structures are increasingly favored to protect brand equity.
• Cross‑Border Health Trade: The deal reflects sustained European‑to‑China healthcare brand licensing activity, as family‑owned EU manufacturers seek growth abroad through local exclusive partners rather than direct market entry.
• Luyan Pharma Growth Vector: Securing an exclusive international brand strengthens Luyan Pharma’s product portfolio beyond traditional pharmacy retail, adding a differentiated, higher‑margin nutraceutical line.
• Execution Catalysts Ahead: Product registration/filing pathways for nutritional supplements in China, channel rollout across pharmacies and e‑commerce, and local marketing of the Synergia brand – specific plans and timelines were not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the exclusive strategic cooperation between Fuzhou Luyan Pharmacy and Curae LAB for the Synergia brand in Greater China, including anticipated commercialization activities. Actual results may differ due to risks including regulatory requirements for nutritional health products, market acceptance, channel execution, and competitive dynamics. Financial terms, sales targets, and launch timelines have not been disclosed.-Fineline Info & Tech